http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10227369-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7008 |
| filingDate | 2014-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4c78ecca0739788d4b72ef68b799f9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75583b51015a491eafc98dd1e93d9f3c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47aa8b06ce90a00bba00684459c9d104 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fb2b289575428c2ea2dc3a8d52e37dc |
| publicationDate | 2019-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10227369-B2 |
| titleOfInvention | Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications |
| abstract | A new class of molecules, C1—OH tributanoylated hexosamines, including, for example, GalNAc, GlcNAc and ManNAc, are demonstrated to increase cartilage-like tissue accumulation by IL-1β-stimulated chondrocytes. Furthermore, all three molecules reduced NFKB1 and IκBα driven gene expression, consistent with NFκB inhibitory properties of these analogs. GalNAc-a exposure produced the greatest ECM accumulation by IL-1β-stimulated chondrocytes. However, GalNAc-a exposure produced an opposite effect on MSC exposure, where a decrease in ECM accumulation was observed. These findings are in support of the function of NFκB signaling during limb development and growth plate chondrogenesis. The present invention shows the capability of this new class of hexosamine analogs as disease-modifying agents for treating cartilage damage. |
| priorityDate | 2013-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 524.